AbCellera Biologics Inc.
ABCL•NASDAQ•Healthcare•Biotechnology

About AbCellera Biologics

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOCarl Hansen
Founded2012
IPO DateDecember 11, 2020
Employees596
CountryCanada
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.abcellera.com
Phone604 559 9005
Address
150 West 4th Ave Vancouver, BC V5Y 1G6 Canada

Corporate Identifiers

CIK0001703057
CUSIP00288U106
ISINCA00288U1066
SIC2834

Leadership Team & Key Executives

Dr. Carl L.G. Hansen Ph.D.
Chief Executive Officer, President and Chairperson
Andrew Booth M.B.A.
Chief Financial Officer
Dr. Veronique Lecault Ph.D.
Chief Technology Officer and Director
Tryn T. Stimart Esq., J.D., M.Sc.
Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer
Andrew Knowles M.Sc.
Vice President of Operations
Marcie Thiessen CPA, CGA
Senior Director of Finance and Accounting
Tiffany Chiu B.Sc., Ph.D.
Vice President of Communications
Graham Craig M.Sc.
Director of Corporate Development
Caitlin Webster CIPD, M.Sc.
Director of Talent Development
Murray McCutcheon Ph.D.
Senior Vice President of Partnering